Tovetumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tovetumab
Monoclonal antibody
Type ?
Source Human
Target CD140a
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6400H9906N1726O2002S54
Molar mass 144.8 kg/mol

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer.[1] It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.[2]

This drug was developed by MedImmune, LLC.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
  2. ^ http://adisinsight.springer.com/drugs/800015253